Ingredient Listing Qty. Unit NDC # Supplier

Similar documents
Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)

Ingredient Listing Qty. Unit NDC # Supplier ml

Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Lidocaine Hydrochloride 2%, Metronidazole 2%, Misoprostol % Topical Ointment (Suspension, 30 g) Ingredient Listing Qty. Unit NDC # Supplier

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier g

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

247 CMR BOARD OF REGISTRATION IN PHARMACY

905 UNIFORMITY OF DOSAGE UNITS

Residual Solvents: FDA/ Regulatory Perspective

History Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.

Student Practical Guide (1) Milk of Magnesia

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

REVISION OF MONOGRAPH ON TABLETS. Tablets

13. SUPPOSITORY Suppository Bases. The active substance is prepared in a suitable bases. An ideal suppository bases should carry:

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

KEYWAX WX1014 RUBBER WAX CONCENTRATE

The Therapeutic Goods Act (1989)

» Croscarmellose Sodium is a cross linked polymer of carboxymethylcellulose sodium.

The Pharmacy Board of Australia s

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

INTRODUCTION. Asthma Drug Delivery - 1

NEPHROCHECK Calibration Verification Kit Package Insert

AgraQuant F.A.S.T. Casein Sandwich ELISA

SOFTISAN 100, 142, 154

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

Stability Study of Hydralazine HCl Oral Solutions Compounded in Humco Oral Vehicles to Determine a Beyond-use Date

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS SULPHUR. FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1973

Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY

Safety Data Sheet. Product Name: DetectX Glutathione Colorimetric Detection Kit. Section 1: Identification. Section 2: Hazard(s) Identification

Model Standards for Pharmacy Compounding of Non-Sterile Preparations

CATEGORY IV MONOGRAPH. Athlete's Foot Treatments

MATERIAL SAFETY DATA SHEET

LABELLING STANDARD ANTIFUNGALS (TOPICAL)

Material Safety Data Sheet:

Food supplement manufacture

Copyright 2017 PureGreens Nutrition Pte Ltd. All rights reserved. Published by Samuel Grenville.

2.2. Label elements There are no statutory labelling requirements under Directive 1999/45/EC, regulation 1272/2008 and regulation 453/2012.

AGP: CP/89 FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS. PHENTHOATE S - a - ethoxycarbonylbenzyl 00-dimethyl phosphorodithioate

NEPHROCHECK Liquid Control Kit Package Insert

MIGLYOL Gel B, Gel T, 840 Gel B

FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. ZINEB Zinc ethylenebisdithiocarbamate

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

INSTRUCTIONS FOR USE AND CARE

Addendum to the 2016 FAO/WHO Manual on pesticide specifications: revised Tablet Specifications for DT, ST and WT

INTERNATIONAL STANDARD

Easy, fast and reliable!

USP Chewable Gels Monographs

Methacrylate adhesive with good thermal stability. Good adhesion even without particular pretreatment. Mix ratio Parts by weight Parts by volume

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Prescribing and Dispensing Drugs

Araldite Advanced Materials. Two component toughened methacrylate adhesive system. Structural Adhesives TECHNICAL DATASHEET

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

Safety Data Sheet. Product Name: DetectX Palladium Screening Fluorescent Detection Kit. Section 1: Identification. Section 2: Hazard(s) Identification

SLEEP AIDS - LABELLING STANDARD

MATERIAL SAFETY DATA SHEET

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. BROMOPHOS 4-bromo-2,5-dichloropheny1 dimethy1 phosphorothioate

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification. Vancomycin Hydrochloride Capsules USP 125 mg and 250 mg. Lupin Limited Goa INDIA

LABELLING FOR DISPENSED PRODUCTS

Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists

SYMBOLOGY. = Manufacturer. = Manufacturing Serial Number. = Manufacturing Lot Number = Catalog Number LOT REF. = Do not resterilize Single Use Only

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

AGP:CP/365,1998 SULFOMETURON METHYL. 2-(4,6-dimethylpyrimidin-2-ylcarbamoylsulfamoyl) benzoic acid, methyl ester

NEPHROCHECK Liquid Control Kit Package Insert

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification. Memantine Hydrochloride Extended Release Capsules 7 mg, 14 mg, 21 mg and 28 mg

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.

The Science of Palatability

MATERIAL SAFETY DATA SHEET

DENTCA Denture Teeth - Directions for Use

Adhere to personal protective measures when giving first aid. First aider: Pay attention to self-protection!

NATURAL HEALTH PRODUCT FUNGAL PROTEASE

The Mechanics of the Dental Anesthetic Cartridge

Material Safety Data Sheet

A. General Appearance

Suppositories. Suppositories: 08/10/2016

FLAVOUR FLOW & ADHESION

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

MATERIAL SAFETY DATA SHEET

Understand Medication and Prescriptions

SAFETY DATA SHEET. Emergency Telephone Number: (24/7/365) English Only

LUPIN LIMITED SAFETY DATA SHEET

STANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS

Curraheen, Co.Cork. Disclaimer: The information contained within this policy is accurate and up-to-date at date of approval.

Material Safety Data Sheet. SPI Supplies Division Structure Probe, Inc. Section 1: Identification. Section 2: Composition. Date Effective: May 1, 2012

Title 17-A: MAINE CRIMINAL CODE

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

EMTRICITABINE AND TENOFOVIR TABLETS

Transcription:

7/12/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tramadol Hydrochloride, EP 0.300 g Stevia Powder 0.15 g Glycerin, USP** 3.0 ml Beef Flavor (Powder) 2.00 g Chew-A-Treat Compound A 11.49 g Chew-A-Treat Compound B 22.98 g **Note: Caprylic/Capric Triglyceride can be used to replace Glycerin to reduce stickiness. SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information Lot Number Expiry Date Light sensitive (protect from light whenever possible): Hygroscopic (protect from moisture whenever possible): Controlled substance (adhere to proper handling and documentation procedures) Preparatory Guidelines Non-Sterile Preparation Sterile Preparation Tramadol Hydrochloride Glycerin, Stevia Powder Tramadol Hydrochloride Processing Error / Testing Considerations: Special Instruction: To account for processing error considerations during preparation, it is suggested to measure an additional 12 to 15% of the required quantities of ingredients. Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

7/12/2015; Page 2 SUGGESTED PREPARATION (for 30 x 1 ml Treats) Weigh and / or measure the following ingredients when appropriate: Ingredient Listing Qty. Unit Multiplication factor (*) : Processing Error Qty. to measure Tramadol Hydrochloride, EP 0.300 g Stevia Powder 0.15 g Glycerin, USP 3.0 ml Beef Flavor (Powder) 2.00 g Chew-A-Treat Compound A 11.49 g Chew-A-Treat Compound B 22.98 g * Takes into account increased batch size conversions and density conversions, if required. Weigh / measure just prior to use. 1. Mold lubrication: Preparatory Instruction A. Lubricate all parts of the Chew-A-Treat Mold with suitable vegetable spray and set aside. Note: Selected vegetable spray needs to be compatible with API(s) and all other ingredients within the formulation. 2. Powder preparation: A. Triturate the Chew-A-Treat Compound B to form a fine, homogeneous powder blend. B. Triturate the Tramadol Hydrochloride to form a fine, homogeneous powder. C. By geometric addition, combine and mix the following ingredients together to form a homogeneous mixture: -Fine, homogeneous powder (Step 2B) -Stevia Powder -Beef Flavor (Powder) -Fine, homogeneous powder blend (Step 2A) D. Transfer the mixture (Step 2C) to a beaker and incrementally add the Glycerin. Specifications: Continuously mix until homogeneous. End result: Homogeneous moist blend. Note: The mixture will have a sand-like texture. If it begins to stick to your stirring device or beaker, you can simply scrape it off and continue mixing.

7/12/2015; Page 3 3. Medium integration: A. Prepare a hot water bath to between 60 C and 65 C. B. Using the hot water bath, melt the Chew-A-Treat Compound A. Specifications: Continuously mix. Maintain temperature between 60 C and 65 C. End result: Homogeneous thick, sticky liquid-like dispersion. C. Incrementally add the homogeneous moist blend (Step 2D) to the melted Chew-A-Treat Compound A (Step 3B). Specifications: Continuously mix until homogeneous. Maintain temperature between 60 C and 65 C. End result: Homogeneous thick, sticky paste-like dispersion. 4. Mold filling: A. Properly lubricate gloves (thumbs, forefingers, and palms) throughout filling. B. Continuing to heat the mixture between 60 to 65 C, remove a marble-sized quantity of the mixture at a time and roll it between your thumb and forefinger to form a cylinder. Pack the 30 mold cavities with these cylinders and scrape off any excess with pre-lubricated plastic scraper. C. Once the treats have been packed down with an extractor, apply a thin layer of lubricant to give a shiny surface. D. Allow the treats to cool at room temperature for at least 15 minutes and then remove them from the mold using the extractor. 5. Validation technique: A. Weigh 6 chewable treats. B. The final weight of each chewable treat shall not be less than 90% and not more than 110% of the theoretically calculated weight 1.36 g in accordance to USP guidelines. 6. Product transfer: Transfer the final product into the specified dispensing container (see Packaging Requirements ).

7/12/2015; Page 4 SUGGESTED PRESENTATION 120 days, based on available stability studies through Medisca*. Estimated Beyond-Use Date Packaging Requirements Manually put into light-resistant Chew-A-Treat blisters and cold seal with foil labels. * BUD is based on the exact execution of the indicated ingredient list, quantities and procedures listed within this formulation. Note: This data is provided for informational purposes only, representing the results of a study of the product stability with various active pharmaceutical ingredients. It does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases the practitioner is advised to consult recognized pharmaceutical compendia and other recognized sources for product formulation and other product characteristics, including stability. MEDISCA Network Inc. makes no warranties or representations with regard to the functioning or appropriateness of this product in any compounded formulation, which use is solely at the discretion and liability of the practitioner. 1 Use as directed. Do not exceed prescribed dose. 7 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. Auxiliary Labels 2 Keep out of reach of children. 8 3 Controlled substance. Dangerous unless used as directed. Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use. 9 Keep at room temperature (20 C 23 C). 4 For Canine use only. 10 Keep in a dry place. 5 Protect from light. 11 May produce psychological and/or physical dependence. 6 May impair mental and/or physical ability. Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. Patient Instructions If allergic reactions occur, consult your pharmacist.

7/12/2015; Page 5 REFERENCES 1. Lozenges/Troches. In: Allen, LV, Jr. The Art, Science and Technology of Pharmaceutical Compounding Third Edition. American Pharmaceutical Association; 2008: 153. 2. Ultram. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2011. 2654. 3. Gelatin. In: Rowe RC. Handbook of Pharmaceutical Excipients, 6 th Edition. American Pharmaceutical Association; 2009: 278. 4. Glycerin. In: Rowe RC. Handbook of Pharmaceutical Excipients, 6 th Edition. American Pharmaceutical Association; 2009: 283. 5. Tramadol Hydrochloride. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 34 th Edition. London, England: The Pharmaceutical Press; 2005: 130. 6. Tramadol (Monograph). In: O Neil MJ. The Merck Index 14 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #9566. 7. Tramadol Hydrochloride. In: Trissel LA. Handbook on Injectable Drugs, 15th Edition. American Society of Health- System Pharmacists; 2009: 559. 8. Tramadol Systemic. Thomson Micromedex. USP DI Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2871. 9. USP <795>. United States Pharmacopeia XXXI / National ry 26. Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314. DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY ISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.